● I am doing phase III clinical trials in Kenya, Indonesia, Mexico and other countries, and I am doing phase I and II clinical trials in Japan.
● Mainly for adults aged 18 to 60, three injections are required.
A new "made in Sichuan" COVID-19 vaccine is currently in the third phase of clinical trials, and it is being applied for marketing as soon as possible. This is what the reporter learned from the "Promotion Meeting of National Major Science and Technology Infrastructure of Translational Medicine (Sichuan) and West China Translational Medicine Forum" held on July 18th.
"Made in Sichuan" COVID-19 vaccine is a recombinant protein COVID-19 vaccine developed by Academician Wei Yuquan. Based on the precise design of structural biology, it targets the binding site between Covid-19 and human cells, and uses insect cells to multiply in culture medium to introduce the gene of coronavirus into insect cells to produce high-quality recombination vaccines protein.
According to Wei Yuquan, academician of China Academy of Sciences and director of the State Key Biological Laboratory of Biotherapy in west china hospital, the Sichuan-made vaccine is undergoing phase III clinical trials in Kenyan, Indonesian, Mexican and other countries, while phase I and II clinical trials are being conducted in Japan. At present, the epidemic situation in COVID-19 is still spreading rapidly all over the world, and there are many mutated viruses. According to the clinical trial data, the vaccine made in Sichuan has great advantages in preventing these mutated viruses.
It is understood that the "made in Sichuan" vaccine is mainly aimed at adults aged 18 to 60, and needs to be injected with three doses.   (Reporter   Li Wei)